Automated pipetting platform
Tuesday, 16 September, 2008
Incorporating advanced pipetting technology in a sleek new design, NIMBUS offers a high-density deck layout in a compact footprint, making it the ideal platform for space-challenged labs seeking an affordable, flexible solution for high performance pipetting. NIMBUS makes quick work of plate replication, low volume reagent addition and serial dilution jobs, yet can easily handle more demanding tasks including MALDI spotting, PCR sample prep, DNA/RNA extraction, ELISA and SPE applications. Designed to fit inside a laminar flow hood, the MicroLab NIMBUS features a 96 channel pipetting head that incorporates Hamilton’s proprietary CO-RE tip attachment technology. A choice of three different deck configurations provides capacity for up to 12 SBS labware positions. Labware density is further enhanced by utilisation of Hamilton’s unique “nested tip rack” design, which allows for stacking of up to four tip racks high on the NIMBUS deck. An optional labware gripper offers extended reach capability and 270º rotation for rapid transport of plates across the deck and seamless integration with plate readers and other peripherals located outside the instrument footprint. Controlling the NIMBUS is made especially easy with a new Graphical User Interface that communicates with the powerful VENUS ONE software, making application programming a breeze. In the coming months, capabilities on the MicroLab NIMBUS will be further expanded through the availability of additional options including integrated barcode reader, hood kit, 384 channel pipetting head and plate stackers.
Bio-Strategy
Tel: 1800 00 84 53
www.bio-strategy.com
'Longevity gene' could reverse damage from rapid aging disease
A gene found in supercentenarians, who live exceptionally long lives, could counteract the...
How a common gene mutation increases liver disease risk
Liver damage can be caused in people after exposure to high levels of acrolein, especially in...
Gene therapy slows Huntington's disease progression in trial
Patients receiving the treatment were found to experience 75% less progression of the disease...

